The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors.

However, in meta-analyses, worsening of mortality endpoints when comparing ESA to placebo [ 23–25 ] or low to high Hb targets [ 26 ] did not reach statistical significance.

also in 111,027 other papers